CONMED (NYSE:CNMD) Releases FY 2026 Earnings Guidance

CONMED (NYSE:CNMD) issued an update on its FY 2026 earnings guidance on Monday morning. The company provided earnings per share guidance of 4.250-4.450 for the period, compared to the consensus earnings per share estimate of 4.460. The company issued revenue guidance of $1.3 billion-$1.4 billion, compared to the consensus revenue estimate of $1.4 billion.

CONMED Trading Up 1.3%

NYSE CNMD opened at $43.46 on Tuesday. The company has a market capitalization of $1.35 billion, a PE ratio of 21.20, a price-to-earnings-growth ratio of 2.83 and a beta of 0.96. The company has a current ratio of 2.10, a quick ratio of 0.95 and a debt-to-equity ratio of 0.85. CONMED has a 1-year low of $38.32 and a 1-year high of $74.70. The firm’s fifty day simple moving average is $42.03 and its 200-day simple moving average is $47.45.

CONMED (NYSE:CNMD) last posted its earnings results on Wednesday, November 5th. The company reported $1.08 earnings per share for the quarter, topping the consensus estimate of $1.05 by $0.03. CONMED had a return on equity of 14.22% and a net margin of 4.75%.The firm had revenue of $337.93 million during the quarter, compared to analyst estimates of $334.76 million. During the same period in the previous year, the company earned $1.05 EPS. The company’s revenue for the quarter was up 6.7% on a year-over-year basis. CONMED has set its FY 2025 guidance at 4.480-4.530 EPS. As a group, sell-side analysts anticipate that CONMED will post 4.35 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the company. Wells Fargo & Company lowered their price target on CONMED from $57.00 to $47.00 and set an “equal weight” rating on the stock in a research report on Thursday, November 6th. Piper Sandler lowered their target price on CONMED from $68.00 to $55.00 and set an “overweight” rating on the stock in a report on Thursday, November 6th. Bank of America cut their target price on shares of CONMED from $65.00 to $52.00 and set a “neutral” rating for the company in a research note on Monday, December 8th. Zacks Research lowered shares of CONMED from a “hold” rating to a “strong sell” rating in a research report on Thursday, January 1st. Finally, Weiss Ratings reiterated a “sell (d+)” rating on shares of CONMED in a research report on Wednesday, October 8th. One investment analyst has rated the stock with a Buy rating, five have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Reduce” and an average target price of $53.67.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Public Sector Pension Investment Board increased its position in CONMED by 7.7% in the 2nd quarter. Public Sector Pension Investment Board now owns 105,513 shares of the company’s stock valued at $5,495,000 after acquiring an additional 7,530 shares in the last quarter. State of Tennessee Department of Treasury grew its stake in shares of CONMED by 17.4% during the second quarter. State of Tennessee Department of Treasury now owns 15,498 shares of the company’s stock valued at $807,000 after purchasing an additional 2,302 shares during the last quarter. AQR Capital Management LLC increased its holdings in shares of CONMED by 19.9% in the first quarter. AQR Capital Management LLC now owns 14,199 shares of the company’s stock valued at $857,000 after purchasing an additional 2,357 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in CONMED by 4.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 18,354 shares of the company’s stock worth $1,108,000 after purchasing an additional 800 shares during the last quarter. Finally, Engineers Gate Manager LP lifted its holdings in CONMED by 490.3% during the 2nd quarter. Engineers Gate Manager LP now owns 22,433 shares of the company’s stock worth $1,168,000 after buying an additional 18,633 shares in the last quarter.

About CONMED

CONMED Corporation (NYSE: CNMD) is a global medical technology company headquartered in Utica, New York. Founded in 1970, CONMED develops, manufactures and markets a broad portfolio of surgical devices and accessories for minimally invasive procedures. The company’s product line supports surgeons and healthcare providers in specialties including orthopedics, general surgery, gastroenterology and gynecology.

CONMED operates two principal segments: Orthopedics, and Visualization & Energy.